Brilliant Violet 510™ anti-human CD64

Catalog # / Size: 2125135 / 25 tests

2125140 / 100 tests

Clone: 10.1

Isotype: Mouse IgG1, κ

Immunogen: Human rheumatoid synovial fluid cells

and fibronectin-purified monocytes.

Reactivity: Human

Preparation: The antibody was purified by affinity

chromatography and conjugated with Brilliant Violet $510^{\, \text{\tiny TM}}$ under optimal conditions. The solution is free of unconjugated Brilliant Violet $510^{\, \text{\tiny TM}}$ and

unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2,


containing 0.09% sodium azide and BSA

(origin USA).

Workshop Number:

VI MA36

Concentration: Lot-specific



Human peripheral blood monocytes were stained with anti-human CD64 (clone 10.1) Brilliant Violet 510^{TM} (filled histogram) or mouse IgG1, κ Brilliant Violet 510^{TM} isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended

Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 510^{TM} excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 510^{TM} is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes:

Clone 10.1 recognizes the EC3 epitope of CD64. Additional reported applications (for the relevant formats) include: blocking of human IgG3 and murine IgG2a binding to $Fc\gamma RI^{2,5,6,11}$ and immunohistochemical staining of acetone-fixed frozen tissue sections¹².

Application References:

1. McMichael A, *et al.* Eds. 1987. Leucocyte Typing III. Oxford University Press. New York.

2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press.

New York. p. 874.

- 3. Kishimoto T, *et al.* Eds. 1997. Leucocyte Typing VI. Garland Publishing Inc. London.
- 4. Holl V, et al. 2004. J. Immunol. 173:6274.
- 5. Hober D, et al. 2002. J. Gen. Virol. 83:2169.
- 6. Cho HJ, et al. 2007. Physiol Genomics 149:60.
- 7. van Tits L, et al. 2005. Arterioscler Thromb Vasc Biol. 25:717. PubMed
- 8. Bruhns P, et al. 2008. Blood 113:3716. PubMed
- 9. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- 10. Carter DL, et al. 1999. Cytometry 37:41. (FC)
- 11. Dougherty GJ, et al. 1987. Eur. J. Immunol. 17:1453.
- 12. Blom AB, et al. 2003. Arthritis Rheum. 48(4):1002-14. (IHC)

Description: CD64 is a 72 kD single chain type I glycoprotein also known as FcγRI and FcR I.

CD64 is a member of the immunoglobulin superfamily and is expressed on monocytes/macrophages, dendritic cells, and activated granulocytes. The expression can be upregulated by IFN- γ stimulation. CD64 binds IgG immune complex. It plays a role in antigen capture, phagocytosis of IgG/antigen complexes, and antibody-dependent cellular cytotoxicity (ADCC).

Antigen

1. Hulett M, et al. 1994. Adv. Immunol. 57:1.

References: 2. van de Winkel J, *et al.* 1993. *Immunol. Today* 14:215.